false
Catalog
2023 World Conference on Lung Cancer (Posters)
P2.07. Real World Efficacy of First-Line Immunothe ...
P2.07. Real World Efficacy of First-Line Immunotherapy +/- Chemotherapy in Advanced NSCLC Stratified by Serum Proteomics - PDF(Slides)
Back to course
Pdf Summary
The INSIGHT study investigated the effectiveness of immune checkpoint inhibitor (ICI) therapy in cancer treatment. The study examined whether a blood-based test called the HIC test could predict the response to ICI therapy. A total of 6611 patients were included in the study, and they received ICI therapy either alone or in combination with chemotherapy. The patients were categorized based on their PD-L1 expression levels and HIC test results. The study evaluated the overall survival (OS) of each patient group. <br /><br />The results showed that patients with high HIC test scores had better overall survival compared to those with low HIC test scores. This was observed in patients treated with both ICI monotherapy and ICI chemotherapy. The HIC test also provided predictive value for overall survival in subgroups based on PD-L1 expression levels.<br /><br />Subgroup analyses based on different clinical characteristics were also conducted. These analyses demonstrated that the HIC test classification remained a significant predictor of overall survival in most subgroups. <br /><br />Overall, the findings suggest that the HIC test can effectively predict the response to ICI therapy and may assist in guiding treatment decisions for cancer patients. However, further research is necessary to validate these findings and explore the underlying mechanisms behind the predictive value of the HIC test.
Asset Subtitle
Wallace Akerley
Meta Tag
Speaker
Wallace Akerley
Topic
Metastatic NSCLC: Immunotherapy - Retrospective
Keywords
INSIGHT study
immune checkpoint inhibitor therapy
HIC test
cancer treatment
blood-based test
response prediction
PD-L1 expression levels
overall survival
ICI monotherapy
ICI chemotherapy
×
Please select your language
1
English